ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
Resolved · credit · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-25. Check what remains unresolved below before relying on it.
What changed relative to expectations?
A successful $446.3M equity capital raise provides multi-year clinical trial runway for ADARx's late-stage siRNA drug pipeline.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factADARx Pharmaceuticals priced its initial public offering of 26.25 million shares at $17.00 per share. |
| What else was confirmed? | Reported factGross proceeds from the offering total approximately $446.3 million. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for ADRX yet — this is the next research task. |
| What would change the assessment? | UnknownADRX First Day Trading Range — Track opening print and volume relative to $17.00 offer price. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · ADARx Pharmaceuticals priced its initial public offering of 26.25 million shares at $17.00 per share.
- · Gross proceeds from the offering total approximately $446.3 million.
- · The stock begins trading on the Nasdaq Global Market under the symbol ADRX on September 25, 2026.
- · ADARx is a late-stage clinical biotechnology firm focused on siRNA therapeutics.
Public research record
Research framework · page evidenceCompleted event assessment
initial market trading liquidity following upsized primary offering
| Type | Claim | Scope |
|---|---|---|
| Assumption | ADARx Pharmaceuticals priced its initial public offering of 26.25 million shares at $17.00 per share. | 2026-09-25 |
| Interpretation | initial market trading liquidity following upsized primary offering | ADRX |
Countercase, invalidators, and sources
Shares open with strong secondary market premium, encouraging subsequent biotech pipeline offerings.
- · ADRX First Day Trading Range — Track opening print and volume relative to $17.00 offer price.
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering · 2026-09-24
What remains unresolved
- Base path
- Stock trades near offering price with balanced institutional volume.
- Adverse path
- Macro rate pressure dampens day-one secondary trading volume below offer price.
- Supportive path
- Shares open with strong secondary market premium, encouraging subsequent biotech pipeline offerings.
- · ADRX First Day Trading Range — Track opening print and volume relative to $17.00 offer price.today
Evidence
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering2026-09-24
“ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing siRNA therapeutics, priced its IPO at $17 per share for 26.25 million shares, generating approximately $446.3 million in gross proceeds. The company will begin trading on Nasdaq under ticker 'ADRX' on September 25, 2026.”
Supports: ADARx priced 26.25M shares at $17/sh for $446.3M gross proceeds; trading begins Sept 25 on Nasdaq as ADRX.